Compare Dolby Laboratories, Inc. (DLB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Dolby Laboratories, Inc. trades at $49.62 (market cap $4.59B), while Regeneron Pharmaceuticals Inc trades at $657.73 (market cap $68.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 15× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays the higher dividend (2.91%). Which is the better fit depends on your goals.
| DLB | REGN | |
|---|---|---|
Market Cap | $4.59B | $68.79B |
Sector | Industrials | Health |
52-Week High | $76.79 | $812.27 |
52-Week Low | $48.51 | $542.52 |
Enterprise Value | $4.04B | $62.74B |
Dividend Yield | 2.91% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $49.36, down 0.88% on the day, with a bearish technical outlook. The company maintains strong fundamentals, including a P/E of 19.59, a net income margin of 17.85%, and consistent earnings beats in recent quarters. Recent news highlights include its role in powering immersive audio for the FIFA World Cup 2026 coverage and recognition as a top supplier by General Motors.
The stock presents a value opportunity given its discount to the analyst consensus price target of $87.50, but faces near-term headwinds from bearish technical signals and cyclical end-market exposure. Upside potential hinges on continued licensing growth and execution, while risks include market sentiment and competitive pressures.
Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.
The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
